Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
In a randomized, double-blind, phase 2 trial involving 155 adults with mild to moderate patchy alopecia areata, the topical nanoparticle formulation STS01 demonstrated a clear dose-response relationship, with the 1% concentration significantly outperforming placebo in hair regrowth efficacy while maintaining a manageable safety profile characterized primarily by mild to moderate skin irritation.